Company Pursues Strategy of Reducing Heart Attack Deaths by Shielding
High-Risk Plaques in Coronary Arteries
DOYLESTOWN, Pa., May 8 /PRNewswire/ --- Prescient Medical, Inc., a privately held medical device company dedicated to reducing deaths from heart attacks, will present new experimental results on the chemical characterization and treatment of rupture-prone or "vulnerable" plaques, with a focus on the vPredict(TM) Optical Catheter System and the vProtect(TM) Luminal Shield, at the upcoming EuroPCR 2008 conference to be held in Barcelona, Spain from May 13 to 16.
The vProtect Luminal Shield was designed by Prescient Medical to treat soft, atherosclerotic lesions that may be at risk of rupture or that have recently ruptured. The self-expanding design of vProtect is a departure from the balloon-expandable stents that are mainstays of current focal treatment for coronary artery disease (CAD). The vProtect Luminal Shield has been designed to limit complications commonly associated with the insertion of stents, including vessel injury, restenosis, neointimal hyperplasia, and thrombosis.
The presentations will be an integral part of a session entitled
"Glimpse Into The Future: Current Understanding of High-Risk
Atherosclerosis Coronary Lesions," which will be held on May 14, 2008 from
13:30 to 16:50 in Room 5 of the conference. Professor Patrick Serruys, head
of the Erasmus Medical Center's Department of Interventional Cardiology,
will co-chair the session, which features presentations from leading
authorities on coronary artery disease, including Dr. Guillermo Tearney, a
distinguished researcher on the development and validation of new optical
diagnostic technologies at Massachusetts General Hospital; and Dr. Juan
Granada, Medical Director at the Jack H. Skirball Center for Cardiovascular
Research. Dr. Tearney will present results from Prescient's vPredict
Optical Catheter System in his presentation, "Spectroscopy Imagi
|SOURCE Prescient Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved